Table 2.
Clinical (n=57) and pathological (n=48) response of all patients and patients in different neoadjuvant therapy group.
| All n=57 (%) | Chemotherapy n=17 (%) | Immunotherapy n=30 (%) | Targeted therapy n=10 (%) | P-value | |
|---|---|---|---|---|---|
| Clinical response | 0.358* | ||||
| CR | 2 (3.5) | 1 (5.9) | 1 (3.3) | 0 (0) | |
| PR | 34 (59.6) | 7 (41.2) | 19 (63.3) | 8 (80.0) | |
| SD | 14 (24.6) | 6 (35.3) | 6 (20) | 2 (20.0) | |
| PD | 7 (12.3) | 3 (17.6) | 4 (13.3) | 0 (0) | |
| Clinical tumor regression (%) | 0.734 | ||||
| Mean ± SD | 29.9 ± 26.6 a | 27.8 ± 27.3 a | 32.5 ± 28.8 | 25.7 ± 18.7 | |
| (range) | (-45.7-100.0) | (0.0-100.0) | (-45.7-100.0) | (0.0-64.0) | |
| n=48 (%) | n=13 (%) | n=26 (%) | n=9 (%) | ||
| Pathological response | 0.122* | ||||
| CR | 5 (10.4) | 0 (0) | 5 (19.2) | 0 (0) | |
| PR | 26 (54.2) | 8 (61.5) | 13 (50.0) | 5 (55.6) | |
| SD | 15 (31.3) | 5 (38.5) | 6 (23.1) | 4 (44.4) | |
| PD | 2 (4.2) | 0 (0) | 2 (7.7) | 0 (0) | |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
*likelihood ratio.
a
One patient in the chemotherapy arm was reported to have disease progression by the investigator, but precise measurement of the lesions was impeded by the infiltrative tumor border configuration. The patient was therefore excluded from the analysis of tumor regression.